The global pen needles market size was valued at USD 4.8 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 9.9 billion by 2033, at a CAGR of 9.4% from 2026 to 2033. Europe pen needles market held the largest share of 36.4% of the global pen needles market in 2025. The increasing prevalence of diabetes is driving the demand for pen needles.
According to the International Diabetes Federation (IDF), the number of people living with diabetes worldwide is projected to reach approximately 642 million by 2040, positioning the pen needles market for significant growth. As diabetes rates rise globally, the demand for efficient insulin delivery solutions is expected to fuel the market expansion at a strong rate over the forecast period. Pen injectors are widely used by diabetic individuals to deliver insulin or other medications, making them a preferred choice for diabetes management. The global surge in diabetes cases, particularly linked to the growing obesity epidemic, has greatly influenced the demand for insulin pens and, by extension, pen needles. Obesity is considered a major risk factor for diabetes. According to Diabetes.co.uk, it accounts for 80-85% of the risk of developing Type 2 diabetes. As the global population becomes increasingly obese, the incidence of diabetes has been rising, creating a large demand for insulin delivery devices such as pen needles.
Technological advancements and continuous innovation in pen needles are further driving market growth, as manufacturers focus on improving patient comfort, safety, and ease of use. Key developments include ultra-fine needles, shorter needle lengths to minimize pain, and advanced designs that reduce the risk of intramuscular injections. Companies are also introducing features such as smoother and flatter needle bases for improved skin contact, along with safety mechanisms that prevent accidental needlestick injuries. For instance, in November 2024, evercare pen needles were introduced as an advanced solution for type I diabetes patients. These pen needles are designed to enhance patient comfort, lower the risk of intramuscular injections, and reduce accidental needlestick injuries. In addition, the product features a wider grip design, making it especially convenient and user-friendly for elderly patients and individuals with limited dexterity.
The market is expected to continue expanding, driven by the increasing global prevalence of diabetes, the growing obesity epidemic, and continuous innovations in needle technology. As more patients switch from syringes to pen needles for insulin delivery, the demand for these devices likely to remain high. The industry is expected to see further advancements that improve patient comfort, safety, and the overall effectiveness of diabetes management. Companies in the pen needles market must continue to focus on product innovation and ensuring a steady supply to meet the needs of a growing diabetic population worldwide.
Regulatory frameworks and product approval processes play a crucial role in shaping product development, market entry strategies, and patient safety standards within the pen needles market. Regulatory approvals, particularly FDA clearances, are essential for ensuring the safety, quality, and effectiveness of medical devices before commercialization. For instance, in January 2024, KB received FDA 510(k) clearance for its Safety Insulin Pen Needle, highlighting the growing emphasis on regulatory compliance across the industry. Such approvals assist companies strengthen their product portfolios while enhancing confidence among healthcare providers and patients. In addition, stringent regulatory standards encourage manufacturers to develop safer, more reliable, and technologically advanced pen needle solutions, thereby supporting overall market growth.
Strategic mergers, acquisitions, and business expansion activities are increasingly influencing the competitive landscape of the pen needles market as companies aim to strengthen their technological expertise, broaden product offerings, and expand their global footprint. For instance, in August 2024, MTD Group acquired Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems businesses. Through this acquisition, MTD increased its production capacity to more than 2.5 billion units and further strengthened its diabetes and obesity care portfolio by integrating Ypsomed’s operations into its European network. Such strategic initiatives help companies improve operational capabilities, enhance manufacturing efficiency, and accelerate product innovation, thereby intensifying market competition and supporting long-term industry growth.
This product will be delivered within 1-3 business days.
According to the International Diabetes Federation (IDF), the number of people living with diabetes worldwide is projected to reach approximately 642 million by 2040, positioning the pen needles market for significant growth. As diabetes rates rise globally, the demand for efficient insulin delivery solutions is expected to fuel the market expansion at a strong rate over the forecast period. Pen injectors are widely used by diabetic individuals to deliver insulin or other medications, making them a preferred choice for diabetes management. The global surge in diabetes cases, particularly linked to the growing obesity epidemic, has greatly influenced the demand for insulin pens and, by extension, pen needles. Obesity is considered a major risk factor for diabetes. According to Diabetes.co.uk, it accounts for 80-85% of the risk of developing Type 2 diabetes. As the global population becomes increasingly obese, the incidence of diabetes has been rising, creating a large demand for insulin delivery devices such as pen needles.
Technological advancements and continuous innovation in pen needles are further driving market growth, as manufacturers focus on improving patient comfort, safety, and ease of use. Key developments include ultra-fine needles, shorter needle lengths to minimize pain, and advanced designs that reduce the risk of intramuscular injections. Companies are also introducing features such as smoother and flatter needle bases for improved skin contact, along with safety mechanisms that prevent accidental needlestick injuries. For instance, in November 2024, evercare pen needles were introduced as an advanced solution for type I diabetes patients. These pen needles are designed to enhance patient comfort, lower the risk of intramuscular injections, and reduce accidental needlestick injuries. In addition, the product features a wider grip design, making it especially convenient and user-friendly for elderly patients and individuals with limited dexterity.
The market is expected to continue expanding, driven by the increasing global prevalence of diabetes, the growing obesity epidemic, and continuous innovations in needle technology. As more patients switch from syringes to pen needles for insulin delivery, the demand for these devices likely to remain high. The industry is expected to see further advancements that improve patient comfort, safety, and the overall effectiveness of diabetes management. Companies in the pen needles market must continue to focus on product innovation and ensuring a steady supply to meet the needs of a growing diabetic population worldwide.
Regulatory frameworks and product approval processes play a crucial role in shaping product development, market entry strategies, and patient safety standards within the pen needles market. Regulatory approvals, particularly FDA clearances, are essential for ensuring the safety, quality, and effectiveness of medical devices before commercialization. For instance, in January 2024, KB received FDA 510(k) clearance for its Safety Insulin Pen Needle, highlighting the growing emphasis on regulatory compliance across the industry. Such approvals assist companies strengthen their product portfolios while enhancing confidence among healthcare providers and patients. In addition, stringent regulatory standards encourage manufacturers to develop safer, more reliable, and technologically advanced pen needle solutions, thereby supporting overall market growth.
Strategic mergers, acquisitions, and business expansion activities are increasingly influencing the competitive landscape of the pen needles market as companies aim to strengthen their technological expertise, broaden product offerings, and expand their global footprint. For instance, in August 2024, MTD Group acquired Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems businesses. Through this acquisition, MTD increased its production capacity to more than 2.5 billion units and further strengthened its diabetes and obesity care portfolio by integrating Ypsomed’s operations into its European network. Such strategic initiatives help companies improve operational capabilities, enhance manufacturing efficiency, and accelerate product innovation, thereby intensifying market competition and supporting long-term industry growth.
Global Pen Needles Market Report Segmentation
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, the analyst has segmented the global pen needles market report based on product, needle length, therapy, and region:Product Outlook (Revenue, USD Billion, 2021-2033)
- Standard Pen Needles
- Safety Pen Needles
Needle Length Outlook (Revenue, USD Billion, 2021-2033)
- 4mm
- 5mm
- 6mm
- 8mm
- 10mm
- 12mm
Therapy Outlook (Revenue, USD Billion, 2021-2033)
- Insulin
- Glucagon-like-peptide-1
- Growth Hormone
Regional Outlook (Revenue, USD Billion, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pen Needles Market Variables, Trends & Scope
Chapter 4. Pen Needles Market: Product Estimates & Trend Analysis
Chapter 5. Pen Needles Market: Needle Length Estimates & Trend Analysis
Chapter 6. Pen Needles Market: Therapy Estimates & Trend Analysis
Chapter 7. Pen Needles Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Novo Nordisk A/S
- Becton Dickinson and Company
- Terumo Corp.
- Owen Mumford Ltd.
- Ypsomed
- B. Braun Melsungen AG
- HTL-STREFA
- UltiMed, Inc.
- Allison Medical, Inc.
- Artsana S.p.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 170 |
| Published | June 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 4.8 Billion |
| Forecasted Market Value ( USD | $ 9.9 Billion |
| Compound Annual Growth Rate | 9.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
